Global pharmaceutical major Eli Lilly, who derives 60% of its Indian revenues from the insulin segment, is planning to launch a few anti-diabetic drugs. Following the launch of the exenatide injection in the Indian market, Lilly is now eyeing the type II segment. The global major is carrying out the phase-3 clinical trials for inhaled insulin system for the type-I and type-II diabetes.
?We are conducting random studies to evaluate safety and efficacy of the inhaled insulin system compared with injected pre-meal insulin,? said Sandeep Gupta, chairman & managing director of Lilly India. ?We have planned to launch five to six new drugs in the next 5-6 years. All these are in various stages of development–from pre-clinical to stage-3 clinical trials,? he said. The number of diabetic patients in India is about 30 lakh.
